IP Library Granted Patent US 12,700,508
Granted Patent B2
US 12,700,508 · App. 18/299,049 · Granted Aug 4, 2026

Artificial intelligence based cardiac event predictor systems and methods

Inventors: Noah Zimmerman (Redwood City, CA); Brandon Fornwalt (Chicago, IL); John Pfeifer (Chicago, IL); Ruijun Chen (Chicago, IL); Arun Nemani (Chicago, IL); Greg Lee (Chicago, IL); Steve Steinhubl (Chicago, IL); Christopher Haggerty (Danville, PA); Sushravya Raghunath (Danville, PA); Alvaro Ulloa-Cerna (Danville, PA); Linyuan Jing (Danville, PA); Thomas Morland (Danville, PA)
Assignees: Tempus AI, Inc.; Geisinger Clinic
G16H50/30A61B5/0006A61B5/28A61B5/318A61B5/7275G16H50/20G06F18/2155
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,700,508
App. No.
18/299,049
Filed
Apr 12, 2023
Granted
Aug 4, 2026
Kind
B2
Art Unit
3796
USPC
600/301
Abstract

A method and system for determining cardiac disease risk from electrocardiogram trace data is provided. The method includes receiving electrocardiogram trace data associated with a patient, the electrocardiogram trace data having an electrocardiogram configuration including a plurality of leads. One or more leads of the plurality of leads that are derivable from a combination of other leads of the plurality of leads are identified, and a portion of the electrocardiogram trace data does not include electrocardiogram trace data of the one or more leads. The portion of the electrocardiogram data is provided to a trained machine learning model, to evaluate the portion of the electrocardiogram trace data with respect to one or more cardiac disease states. A risk score reflecting a likelihood of the patient being diagnosed with a cardiac disease state within a predetermined period of time is generated by the trained machine learning model based on the evaluation.

Claims (51)

1 . A method for determining cardiac disease risk from electrocardiogram trace data, comprising:

receiving electrocardiogram trace data associated with a subject, the electrocardiogram trace data having an electrocardiogram configuration including a plurality of leads and a time interval and comprising, for each lead included in the plurality of leads, voltage data associated with at least a portion of the time interval;

identifying, from the plurality of leads of the electrocardiogram trace data, one or more first leads of the plurality of leads including electrocardiogram trace data that is derivable from the voltage data associated with a combination of other leads of the plurality of leads, wherein second leads of the plurality of leads are other than the one or more first leads;

determining a first set of electrocardiogram trace data based on a first subset of the second leads;

determining a second set of electrocardiogram trace data based on a second subset of the second leads, wherein the first subset is different from the second subset;

inputting the electrocardiogram trace data associated with the second leads into a trained machine learning model comprising a plurality of branches, the machine learning model being configured to receive the first set of electrocardiogram trace data at a first branch of the plurality of branches and receive the second set of electrocardiogram trace data at a second branch of the plurality of branches, wherein the first branch of the plurality of branches has a different size than the second branch of the plurality of branches, the machine learning model being trained to generate predictions associated with cardiac disease risk based on input data; and

generating, by the trained machine learning model and based on evaluating portions of the electrocardiogram trace data associated with the second leads at respective branches of the trained machine learning model, a risk score reflecting a likelihood of the subject being diagnosed with a cardiac disease state within a predetermined period of time from when the electrocardiogram trace data associated with the subject was generated, the predetermined period of time being less than or equal to one year; and

outputting the risk score to at least one of a memory or a display.

2 . The method of claim 1 , further comprising:

generating, based on the risk score and an additional risk score associated with a second cardiac disease state, a composite prediction, the composite prediction reflecting a likelihood that the subject will be diagnosed with either of the cardiac disease state or the second cardiac disease state within the predetermined period of time from when the electrocardiogram trace data associated with the subject was generated.

3 . The method of claim 1 , wherein the electrocardiogram trace data associated with the subject does not include features indicating that the subject has the cardiac disease state when the electrocardiogram trace data associated with the subject was generated.

4 . The method of claim 1 , further comprising generating, based on the risk score, a treatment recommendation; and

outputting the treatment recommendation to at least one of the memory or the display,

wherein the treatment recommendation includes a recommendation to perform additional cardiac monitoring for the subject.

5 . The method of claim 1 , further comprising:

training a convolutional neural network on a first plurality of subjects and a second plurality of subjects, wherein a time between a date of a recorded ECG and a diagnosis of a cardiac disease for each of the first plurality of subjects is less than a diagnosis threshold, and a time between a date of a recorded ECG and a diagnosis of the cardiac disease for each of the second plurality of subjects is greater than the diagnosis threshold, and wherein a time between a date of a particular recorded ECG and a diagnosis of the cardiac disease that is less than the diagnosis threshold is indicative of the cardiac disease being active at the date of the particular recorded ECG; and

providing the trained convolutional neural network as the trained machine learning model.

6 . The method of claim 5 , further comprising:

refining the trained convolutional neural network using only the second plurality of subjects, wherein the diagnosis threshold is selected from a number of days.

7 . The method of claim 5 , wherein the cardiac disease is aortic stenosis.

8 . The method of claim 1 , wherein the trained machine learning model is selected based at least in part on a severity of the cardiac disease state the generated risk score represents.

9 . The method of claim 1 , wherein the trained machine learning model is based on training data associated with a plurality of clinical sites, and wherein the method further comprises training the machine learning model using subject data associated with one site of the plurality of clinical sites and testing the trained machine learning model on the remaining sites of the plurality of clinical sites.

10 . The method of claim 1 , wherein the electrocardiogram trace data associated with the subject comprises ECG data selected from one or more of acute myocardial infarction, atrial fibrillation, atrial flutter, complete block, early repolarization, fascicular block, first-degree atrioventricular block, intraventricular conduction block, left bundle branch block, right bundle branch block, ischemia, left anterior descending artery ischemia, right bundle branch block, low QRS, left ventricular hypertrophy, non-specific ST-T wave, Non-specific T wave, other bradycardia, premature atrial contractions, pacemaker, poor tracing, prior infarction, prior myocardial infarction anterior, prolonged QT, premature ventricular contractions, right axis deviation, second degree atrioventricular block, sinus bradycardia, supraventricular tachycardia, tachycardia, tachyarrhythmia, T inversion, or ventricular tachycardia.

11 . The method of claim 1 , wherein the trained machine learning model is a composite model, and wherein training the composite model comprises:

generating a subject timeline for each subject;

anchoring each respective subject timeline to a date of occurrence of an echocardiogram; and

labeling each respective subject as having a positive or negative ECG based at least in part on a date of an ECG with respect to the date of occurrence of the echocardiogram.

12 . The method of claim 11 , further comprising excluding subjects from training after a censoring event is detected in the subject timeline.

13 . The method of claim 1 , wherein the cardiac disease state is one of aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, reduced ejection fraction, increased interventricular septal thickness, cardiac amyloidosis, or stroke.

14 . The method of claim 1 , wherein the trained machine learning model is trained to evaluate subject data of an electronic health record with respect to one or more cardiac disease states.

15 . The method of claim 1 , wherein the electrocardiogram trace data evaluated at the first branch is acquired over a first time period, the first time period being twice as long as time periods associated with the electrocardiogram trace data evaluated at each of the other branches of the plurality of branches.

16 . The method of claim 1 , wherein a portion of the electrocardiogram trace data evaluated at the first branch is reconstructed, at least in part, from the one or more first leads.

17 . A system comprising:

a computer including a processing device, the processing device configured to:

receive electrocardiogram trace data associated with a subject, the electrocardiogram trace data having an electrocardiogram configuration including a plurality of leads and a time interval and comprising, for each lead included in the plurality of leads, voltage data associated with at least a portion of the time interval;

identify, from the plurality of leads of the electrocardiogram trace data, one or more first leads of the plurality of leads including electrocardiogram trace data that is derivable from the voltage data associated with a combination of other leads of the plurality of leads, wherein second leads of the plurality of leads are other than the one or more first leads;

determining a first set of electrocardiogram trace data based on a first subset of the second leads;

determining a second set of electrocardiogram trace data based on a second subset of the second leads, wherein the first subset is different from the second subset;

input the electrocardiogram trace data associated with the second leads into a trained machine learning model comprising a plurality of branches, the machine learning model being configured to receive the first set of electrocardiogram trace data at a first branch of the plurality of branches and receive the second set of electrocardiogram trace data at a second branch of the plurality of branches, wherein the first branch of the plurality of branches has a different size than the second branch of the plurality of branches, the machine learning model being trained to generate predictions associated with cardiac disease risk based on input data;

generate, by the trained machine learning model and based on evaluating portions of the electrocardiogram trace data associated with the second leads at respective branches of the trained machine learning model, a risk score reflecting a likelihood of the subject being diagnosed with a cardiac disease state within a predetermined period of time from when the electrocardiogram trace data associated with the subject was generated, the predetermined period of time being up to one year; and

output the risk score to at least one of a memory or a display.

18 . The system of claim 17 , wherein the cardiac disease state is one of aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, reduced ejection fraction, increased interventricular septal thickness, cardiac amyloidosis, or stroke.

19 . A non-transitory computer readable medium, comprising instructions that, when executed by a processing device, cause a computer to:

receive electrocardiogram trace data associated with a subject, the electrocardiogram trace data having an electrocardiogram configuration including a plurality of leads and a time interval and comprising, for each lead included in the plurality of leads, voltage data associated with at least a portion of the time interval;

identify, from the plurality of leads of the electrocardiogram trace data, one or more first leads of the plurality of leads including electrocardiogram trace data that is derivable from the voltage data associated with a combination of other leads of the plurality of leads, wherein second leads of the plurality of leads are other than the one or more first leads;

determining a first set of electrocardiogram trace data based on a first subset of the second leads;

determining a second set of electrocardiogram trace data based on a second subset of the second leads, wherein the first subset is different from the second subset;

input the electrocardiogram trace data associated with the second leads into a trained machine learning model comprising a plurality of branches, the machine learning model being configured to receive the first set of electrocardiogram trace data at a first branch of the plurality of branches and receive the second set of electrocardiogram trace data at a second branch of the plurality of branches, wherein the first branch of the plurality of branches has a different size than the second branch of the plurality of branches, the machine learning model being trained to generate predictions associated with cardiac disease risk based on input data;

generate, by the trained machine learning model and based on evaluating portions of the electrocardiogram trace data associated with the second leads at respective branches of the trained machine learning model, a risk score reflecting a likelihood of the subject being diagnosed with a cardiac disease state within a predetermined period of time from when the electrocardiogram trace data associated with the subject was generated, the predetermined period of time being less than or equal to one year; and

output the risk score to at least one of a memory or a display.

20 . The non-transitory computer readable medium of claim 19 , wherein the cardiac disease state is one of aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, reduced ejection fraction, increased interventricular septal thickness, cardiac amyloidosis, or stroke.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 14, 2026
From: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
To: TEMPUS AI, INC. (F/K/A TEMPUS LABS, INC.)
Reel/Frame 074653/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2026
From: ZIMMERMAN, NOAH; NEMANI, ARUN; LEE, GREG; STEINHUBL, STEVE
To: TEMPUS LABS, INC.
Reel/Frame 074299/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2026
From: HAGGERTY, CHRISTOPHER; RAGHUNATH, SUSHRAVYA; ULLOA-CERNA, ALVARO; JING, LINYUAN; MORLAND, THOMAS; CHEN, RUIJUN; FORNWALT, BRANDON; PFEIFER, JOHN
To: GEISINGER CLINIC
Reel/Frame 074299/0741 →
SECURITY INTEREST Recorded Oct 13, 2023
From: TEMPUS LABS, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 065209/0711 →
Continuity (9)
Continuation 17829356 · May 31, 2022
Continuation In Part 17026092 · Sep 18, 2020
Provisional Application 63224850 · Jul 22, 2021
Provisional Application 63202436 · Jun 10, 2021
Provisional Application 63194923 · May 28, 2021
Provisional Application 63013897 · Apr 22, 2020
Provisional Application 62924529 · Oct 22, 2019
Provisional Application 62902266 · Sep 18, 2019
Related Publication 20230245782A1 · Aug 3, 2023
References Cited (135)
US 6073046A · Patel · 2000 [cited by examiner]
US 6217525B1 · Medema · 2001 [cited by examiner]
US 7801591B1 · Shusterman · 2010 [cited by applicant]
US 10395772B1 · Lucas et al. · 2019 [cited by applicant]
US 10667680B2 · Gupta et al. · 2020 [cited by applicant]
US 10827982B2 · Sitek · 2020 [cited by applicant]
US 11657921B2 · Zimmerman · 2023 [cited by examiner]
US 11972869B2 · Wagner et al. · 2024 [cited by applicant]
US 20020087088A1 · Brodnick · 2002 [cited by examiner]
US 20070214013A1 · Silverman · 2007 [cited by applicant]
US 20090093686A1 · Hu et al. · 2009 [cited by applicant]
US 20100217144A1 · Brian · 2010 [cited by applicant]
US 20110295134A1 · DeBauche · 2011 [cited by applicant]
US 20110319724A1 · Cox · 2011 [cited by examiner]
US 20140107501A1 · Komanduri · 2014 [cited by examiner]
US 20150112182A1 · Sharma et al. · 2015 [cited by applicant]
US 20150235143A1 · Eder · 2015 [cited by applicant]
US 20150324527A1 · Siegel et al. · 2015 [cited by applicant]
US 20160022162A1 · Ong et al. · 2016 [cited by applicant]
US 20160135706A1 · Sullivan et al. · 2016 [cited by applicant]
US 20160143553A1 · Chien · 2016 [cited by examiner]
US 20170071483A1 · Wang · 2017 [cited by examiner]
US 20170095217A1 · Hubert · 2017 [cited by examiner]
US 20170105683A1 · Xue · 2017 [cited by examiner]
US 20170112401A1 · Rapin · 2017 [cited by examiner]
US 20170357756A1 · Fidone et al. · 2017 [cited by applicant]
US 20180060522A1 · Petterson · 2018 [cited by examiner]
US 20180085046A1 · Ashoori · 2018 [cited by examiner]
US 20180203978A1 · Basu · 2018 [cited by examiner]
US 20180333104A1 · Sitek · 2018 [cited by applicant]
US 20190046038A1 · Weinstein · 2019 [cited by examiner]
US 20190171936A1 · Karras et al. · 2019 [cited by applicant]
US 20190175118A1 · Gregg · 2019 [cited by examiner]
US 20190183431A1 · Attia · 2019 [cited by examiner]
US 20200176122A1 · Teplitzky et al. · 2020 [cited by applicant]
US 20200226757A1 · Hare, II et al. · 2020 [cited by applicant]
US 20200337773A1 · Rawlinson et al. · 2020 [cited by applicant]
US 20200353271A1 · Dani et al. · 2020 [cited by applicant]
US 20200397313A1 · Attia et al. · 2020 [cited by applicant]
US 20210000347A1 · Stump · 2021 [cited by applicant]
US 20210027194A1 · Monaghan et al. · 2021 [cited by applicant]
US 20210059540A1 · Peterson et al. · 2021 [cited by applicant]
US 20210076960A1 · Fornwalt · 2021 [cited by examiner]
US 20210085215A1 · Auerbach et al. · 2021 [cited by applicant]
US 20210085397A1 · Passerini et al. · 2021 [cited by applicant]
US 20210089921A1 · Aghdasi et al. · 2021 [cited by applicant]
US 20210110930A1 · Park et al. · 2021 [cited by applicant]
US 20210125722A1 · Sherkat et al. · 2021 [cited by applicant]
US 20210150693A1 · Fornwalt et al. · 2021 [cited by applicant]
US 20210153761A1 · Jung et al. · 2021 [cited by applicant]
US 20210259560A1 · Venkatraman et al. · 2021 [cited by applicant]
US 20210345934A1 · Landgraf et al. · 2021 [cited by applicant]
US 20220189636A1 · Wagner et al. · 2022 [cited by applicant]
US 20220229071A1 · Rhyne et al. · 2022 [cited by applicant]
US 20240164688A1 · Asirvatham et al. · 2024 [cited by applicant]
CN 106510686A · 2017 [cited by applicant]
KR 20200077852A · 2020 [cited by applicant]
WO 2019118640A1 · 2019 [cited by applicant]
WO 2020004369A1 · 2020 [cited by applicant]
WO 2021071142A1 · 2021 [cited by applicant]
European Patent Office, Extended Search Report, Application No. 20866017.5, Sep. 20, 2023, 7 pages. [cited by applicant]
Alonso et al., Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: The Charge-AF Consortium, J Am Heart Assoc, 2013, 2:e000102, 11 pages. [cited by applicant]
Arvanitis et al., Identification of V1221 (Val122lle) Transthyretin Cardiac Amyloidosis (ATTR) Using Serum Retinol-Binding Protein 4 (RBP4) and a Clinical Prediction Model, JAMA Cardiol., 2017, 2(3):305-313. [cited by applicant]
Ashburner et al., Design and Rationale of a Pragmatic Trial Integrating Routine Screening for Atrial Fibrillation at Primary Care Visits: The Vital-AF Trial, American Heart Journal, 2019, 215:147-156. [cited by applicant]
Attia et al., An Artificial Intelligence-Enabled ECG Algorithm for the Identification of Patients with Atrial Fibrillation During Sinus Rhythm: A Retrospective Analysis of Outcome Prediction, The Lancet, 2019, 394(10201… [cited by applicant]
Britton et al., Non-Rheumatic Atrial Fibrillation as a Risk Factor for Stroke, Stroke, 1985, 16(2):182-188. [cited by applicant]
Chamberlain et al., A Clinical Risk Score for Atrial Fibrillation in a Biracial Prospective Cohort (From the Atherosclerosis Risk in Communities [ARIC] Study, Am J Cardiol, 2011, 107(1):85-91. [cited by applicant]
Chen et al., XGBoost: A Scalable Tree Boosting System, Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2016, pp. 785-794. [cited by applicant]
clinicaltrials.gov, Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (East), NCT01288352, 2011, 10 pages. [cited by applicant]
clinicaltrials.gov, A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke, NCT04126486, 2019, 6 pages. [cited by applicant]
Connolly et al., Dabigatran Versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, 2009, 361:1139-1151. [cited by applicant]
Cox, Regression Models with Life Tables. Journal of the Royal Statistical Society, Series B (Methodological), 1972, 34(2):187-220. [cited by applicant]
Duchi et al., Adaptive Subgradient Methods for Online Learning and Stochastic Optimization, Journal of Machine Learning Research, 2011, 12:2121-2159. [cited by applicant]
Freedman et al., Stroke Prevention in Atrial Fibrillation, The Lancet, 2016, 388(10046):806-817. [cited by applicant]
Friberg et al., High Prevalence of Atrial Fibrillation Among Patients with Ischemic Stroke, Stroke, 2005, 45:2599-2605. [cited by applicant]
Gladstone et al., Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial, JAMA Cardiology, 2021, 6(5):558-567. [cited by applicant]
Gopinathannair et al., Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management, J Am Coll Cardiol., 2015, 66:1714-1728. [cited by applicant]
Granger et al., Apixaban Versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, 2011, 365:981-992. [cited by applicant]
Guo et al., Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation, Journal of the American College of Cardiology, 2019, 74(19):2365-2375. [cited by applicant]
Hannon et al., Stroke Associated with Atrial Fibrillation—Incidence and Early Outcomes in the North Dublin Population Stroke Study, Cerebrovascular Diseases, 2010, 29:43-49. [cited by applicant]
Hart et al., Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, 2007, 146:857-867. [cited by applicant]
Healey et al., Subclinical Atrial Fibrillation and the Risk of Stroke, New England Journal of Medicine, 2012, 366:120-129. [cited by applicant]
Heeringa et al., Prevalence, Incidence and Lifetime Risk of Atrial Fibrillation: The Rotterdam Study, European Heart Journal, 2006, 27:949-953. [cited by applicant]
Hindricks et al., 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal, 2020, 4… [cited by applicant]
Hobbs et al., A Randomised Controlled Trial and Cost-Effectiveness Study of Systematic Screening (Targeted and Total Population Screening) Versus Routine Practice for the Detection of Atrial Fibrillation in People Aged … [cited by applicant]
Huda et al., A Machine Learning Model for Identifying Patients at Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, Nature Communications, 2021, 12:2725, pp. 1-12. [cited by applicant]
Huizar et al., Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review, J Am Coll. Cardiol., 2019, 73(18):2328-2344. [cited by applicant]
Ioffe et al., Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift, In International Conference on Machine Learning, 2015, pp. 448-456. [cited by applicant]
Kaplan et al., Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, 1958, 53(282):457-481. [cited by applicant]
Khurshid et al., ECG-Based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation, Circulation, 2022, 145(2):122-133. [cited by applicant]
Kirchhof et al., 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS, European Heart Journal, 2016, 37:2893-2962. [cited by applicant]
Koltowski et al., Kardia Mobile Applicability in Clinical Practice: A Comparison of Kardia Mobile and Standard 12-lead Electrocardiogram Records in 100 Consecutive Patients of a Tertiary Cardiovascular Care Center, Card… [cited by applicant]
Kottkamp, Human Atrial Fibrillation Substrate: Towards a Specific Fibrotic Atrial Cardiomyopathy, European Heart Journal, 2013, 34:2731-2738. [cited by applicant]
Krahn et al., The Natural History of Atrial Fibrillation: Incidence, Risk Factors, and Prognosis in the Manitoba Follow-Up Study, American Journal of Medicine, 1995, 98::476-484. [cited by applicant]
Kyriakou et al., Diagnosis of Cardiac Amyloidosis: A Systematic Review on the Role of Imaging and Biomarkers, BMC Cardiovascular Disorders, 2018, 18:221, pp. 1-11. [cited by applicant]
Lin et al., Newly Diagnosed Atrial Fibrillation and Acute Stroke: The Framingham Study, Stroke, 1995, 26:1527-1530. [cited by applicant]
Lin et al., Network in Network, In 2nd International Conference on Learning Representations, ICLR 2014—Conference Track Proceedings. 2014, 10 pages. [cited by applicant]
Lip et al., Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation, Chest, 2010, 137… [cited by applicant]
Lloyd-Jones et al., Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study, Circulation, 2004, 110:1042-1046. [cited by applicant]
Martini et al., Deep Learning to Diagnose Cardiac Amyloidosis from Cardiovascular Magnetic Resonance, Journal of Cardiovascular Magnetic Resonance, 2020, 22:84, pp. 1-11. [cited by applicant]
Meschia et al., Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association, Stroke, 2014, 45:3754-3832. [cited by applicant]
Morandi et al., X-ray, Lensing and Sunyaev-Zel'dovich Triaxial Analysis of Abell 1835 Out to R200, Mon Not R Astron Soc., 2012, 425:2069-2082. [cited by applicant]
Page et al., Asymptomatic Arrhythmias in Patients with Symptomatic Paroxysmal Atrial Fibrillation and Paroxysmal Supraventricular Tachycardia, Circulation, 1994, 89:224-227. [cited by applicant]
Patel et al., Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, 2011, 365:883-891. [cited by applicant]
Perez et al., Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation, New England Journal of Medicine, 2019, 381:1909-1917. [cited by applicant]
Poterucha et al., Deep Learning Analysis of Cardiac Testing for the Detection of Cardiac Amyloidosis, JACC, 2021, 77(18):529. [cited by applicant]
Prechelt, Early Stopping—But When? In: Neural Networks: Tricks of the Trade, Springer, 1998. pp. 55-69. [cited by applicant]
Raghunath et al., Deep Neural Networks can Predict Mortality from 12-lead Electrocardiogram Voltage Data, 2019, arXiv preprint arXiv:1904.07032, pp. 1-11. [cited by applicant]
Raghunath et al., Prediction of Mortality from 12-lead Electro Cardiogram Voltage Data Using a Deep Neural Network, Nature Medicine, 2020, 26(6):886-891. [cited by applicant]
Raghunath et al., Deep Neural Networks can Predict New-Onset Atrial Fibrillation from the 12-lead ECG and Help Identify Those at Risk of Atrial Fibrillation-Related Stroke, Circulation, 2021, 143(13):1287-1298. [cited by applicant]
Reiffel et al., Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The Reveal AF Study, JAMA Cardiology, 2017, 2:1120-1127. [cited by applicant]
Rembold, Number Needed to Screen: Development of a Statistic for Disease Screening, BMJ, 1998, 317:307-312. [cited by applicant]
Schnabel et al., Development of a Risk Score for Atrial Fibrillation in the Community; The Framingham Heart Study, Lancet, 2009, 373:739-745. [cited by applicant]
Schroder et al., Screening and Prostate-Cancer Mortality in a Randomized European Study, New England Journal of Medicine, 2009, 360:1320-1328. [cited by applicant]
Singer et al., ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (Guard-AF): Rationale and Design of the Guard-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day… [cited by applicant]
Siu, Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Annals of Internal Medicine, 2016, 164:279-296. [cited by applicant]
Steinhubl et al., Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial, JAMA, 2018, 320(2):146-155. [cited by applicant]
Stewart et al., A Population-Based Study of the Long-term Risks Associated with Atrial Fibrillation: 20-Year Follow-up of the Renfrew/Paisley Study, American Journal of Medicine, 2002, 113:359-364. [cited by applicant]
Suresh et al., Advanced Cardiac Amyloidosis Associated with Normal Interventricular Septum Thickness: An Uncommon Presentation of Infiltrative Cardiomyopathy, J Am Soc Echocardiogr, 2014, 27(4):440-447. [cited by applicant]
Svennberg et al., Mass Screening for Untreated Atrial Fibrillation: The Strokestop Study, Circulation, 2015, 131(25):2176-2184. [cited by applicant]
Topol, Digital Medicine—What's Lurking in Your Electrocardiogram?, The Lancet, 2021, 397:785. [cited by applicant]
Turakhia et al., Atrial Fibrillation Burden and Short-Term Risk of Stroke: Case-Crossover Analysis of Continuously Recorded Heart Rhythm from Cardiac Electronic Implanted Devices, Circ Arrhythmia Electrophysiol, 2015, 8… [cited by applicant]
US Preventive Services Task Force, Screening for Atrial Fibrillation, US Preventive Services Task Force Recommendation Statement, JAMA, 2022, 327(4):360-367. [cited by applicant]
Weimann et al., Transfer Learning for ECG Classification, Scientific Reports, 2021, 11:5251, pp. 1-12. [cited by applicant]
Wolf et al., Epidemiologic Assessment of Chronic Atrial Fibrillation and Risk of Stroke: The Framingham Study, Neurology, 1978, 28:973-977. [cited by applicant]
Wolf et al., Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study, Stroke, 1991, 22(8):983-988. [cited by applicant]
Youden, Index for Rating Diagnostic Tests, Cancer, 1950, pp. 32-35. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2020/051655, Dec. 22, 2020, 8 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2022/031663, Aug. 19, 2022, 15 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2022/031665, Aug. 19, 2022, 16 pages. [cited by applicant]
PCT International Search Report and Written Opinion, PCT/US2022/031670, Aug. 18, 2022, 9 pages. [cited by applicant]
Apple Inc., De Novo Classification Request for ECG App, 2018, 15 pages. [cited by applicant]
Damy, Thibaud, et al. “Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.” Open heart 3.1 (2016): e000289. [cited by applicant]
Zhang, Kathleen W., et al. “A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.” American heart journal 232 (2021): 137-145. [cited by applicant]
Extended European Search Report in European Application No. 22812343.6; received on Nov. 19, 2024. [cited by applicant]